医学
冠状动脉疾病
抗血小板药物
血栓
疾病
重症监护医学
心脏病学
血管疾病
药品
血小板聚集抑制剂
内科学
氯吡格雷
血小板
心肌梗塞
药理学
作者
Maximilian Tscharre,Thomas Gremmel
标识
DOI:10.1055/s-0042-1758821
摘要
Cardiovascular disease, particularly coronary artery disease (CAD), remains the leading cause of mortality and morbidity in industrialized countries. Platelet activation and aggregation at the site of endothelial injury play a key role in the processes ultimately resulting in thrombus formation with vessel occlusion and subsequent end-organ damage. Consequently, antiplatelet therapy has become a mainstay in the pharmacological treatment of CAD. Several drug classes have been developed over the last decades and a broad armamentarium of antiplatelet agents is currently available. This review portrays the evolution of antiplatelet therapy, and provides an overview on previous and current antiplatelet drugs and strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI